Cell-dependent kinase inhibitor 2A and 2B genetic variability in patients with Alzheimer’s disease

2010 ◽  
Vol 258 (4) ◽  
pp. 704-705
Author(s):  
Francesca Cortini ◽  
Chiara Fenoglio ◽  
Eliana Venturelli ◽  
Chiara Villa ◽  
Francesca Clerici ◽  
...  
Author(s):  
Agnieszka Zabłocka ◽  
Wioletta Kazana ◽  
Marta Sochocka ◽  
Bartłomiej Stańczykiewicz ◽  
Maria Janusz ◽  
...  

AbstractThe negative association between Alzheimer’s disease (AD) and cancer suggests that susceptibility to one disease may protect against the other. When biological mechanisms of AD and cancer and relationship between them are understood, the unsolved problem of both diseases which still touches the growing human population could be overcome. Actual information about biological mechanisms and common risk factors such as chronic inflammation, age-related metabolic deregulation, and family history is presented here. Common signaling pathways, e.g., p53, Wnt, role of Pin1, and microRNA, are discussed as well. Much attention is also paid to the potential impact of chronic viral, bacterial, and fungal infections that are responsible for the inflammatory pathway in AD and also play a key role to cancer development. New data about common mechanisms in etiopathology of cancer and neurological diseases suggests new therapeutic strategies. Among them, the use of nilotinib, tyrosine kinase inhibitor, protein kinase C, and bexarotene is the most promising.


1999 ◽  
Vol 269 (2) ◽  
pp. 67-70 ◽  
Author(s):  
Fabienne Wavrant-De Vrièze ◽  
Richard Crook ◽  
Peter Holmans ◽  
Patrick Kehoe ◽  
Michael J. Owen ◽  
...  

2009 ◽  
Vol 283 (1-2) ◽  
pp. 66-68 ◽  
Author(s):  
Roberto Del Bo ◽  
Serena Ghezzi ◽  
Elio Scarpini ◽  
Nereo Bresolin ◽  
Giacomo Pietro Comi

2021 ◽  
Vol 11 (4) ◽  
pp. 263-276
Author(s):  
Miren Ettcheto ◽  
Amanda Cano ◽  
Elena Sanchez-López ◽  
Ester Verdaguer ◽  
Jaume Folch ◽  
...  

The actual standard treatment for mild-to-moderately severe Alzheimer's disease only attacks its symptoms. Masitinib is a potent and selective phenylaminothiazole-type tyrosine kinase inhibitor which is currently in Phase III studies for the treatment of Alzheimer's disease (AD) with the aim of modifying its evolution and with multiple pharmacological targets such as inhibition of mast cells activity, inhibition of microglia activation, modulation of Aβ and Tau protein signaling pathway and prevention of synaptic damage. Here, we review the preclinical and clinical studies that investigated the administration of masitinib treatment in monotherapy in AD. All research studies revealed positive effects concerning the cognitive functions in AD and generally with good safety and tolerability.


PLoS ONE ◽  
2010 ◽  
Vol 5 (3) ◽  
pp. e9510 ◽  
Author(s):  
Rita J. Guerreiro ◽  
John Beck ◽  
J. Raphael Gibbs ◽  
Isabel Santana ◽  
Martin N. Rossor ◽  
...  

2009 ◽  
Vol 5 (4S_Part_5) ◽  
pp. P149-P149
Author(s):  
Karolien Bettens ◽  
Nathalie Brouwers ◽  
Helen Van Miegroet ◽  
Sebastiaan Engelborghs ◽  
Peter De Deyn ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document